Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
|Videos|July 26, 2011
Kristie Howlett on her Patient Hand Wiping Trial
Author(s)Kristie Howlett, MS, RN
Kristie Howlett from Sutter Roseville Medical Center on her Patient Hand Wiping Trial
Advertisement
Kristie Howlett, MS, RN, CNS, AOCNS®, from Sutter Roseville Medical Center, describes that after a baseline assessment there was only a 30% usage rate of the hand wipes among patients. In order to increase use the study focused on increasing education by creating posters, brochures, and increasing one-on-one education.
Advertisement
Related to this article
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.
Frailty is common among older adults with blood cancers and strongly predicts survival, independent of age.
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5